Makans Limited Pharmaceutical Import Profile — Fiji (DGFT 2022–2026)

Name: Makans Limited Pharmaceutical Import Records from India — 2 Products, $850.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Makans Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $850.0K Trade | TransData Nexus

Makans Limited

Pharmaceutical Importer · Fiji · Respiratory & OTC Focus · $850.0K Total Trade · DGFT Verified

Makans Limited is a pharmaceutical importer based in Fiji with a total trade value of $850.0K across 2 products in 1 therapeutic categories. Based on 17 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Makans Limited sources from 2 verified Indian suppliers, with Lincoln Pharmaceuticals Limited accounting for 99.9% of imports.

Makans Limited — Import Portfolio & Supplier Network

Makans Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Makans Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lincoln Pharmaceuticals Limited	$854.9K	180	99.9%
Meyer Organics Private Limited	$833	2	0.1%

Makans Limited sources from 2 verified Indian suppliers across 148 distinct formulations. The sourcing is — Lincoln Pharmaceuticals Limited accounts for 99.9% of total imports, indicating a strategic single-source relationship.

What Formulations Does Makans Limited Import?

Formulation	Value	Ships
Guaifenesin with bromhexine	$107.5K	4
Anticold tablets (restocin)	$102.6K	3
Co-trimoxazole tablets b.p. (sulphatrim)	$101.2K	3
Metoclopramide injection BP (perilin	$47.3K	3
Betamethasone dipropionate, gentamycin	$43.9K	4
Griseofulvin tablets BP 500 MG	$27.6K	2
Paracetamol tablets BP 500 MG (dolomol)	$22.5K	1
Griseofulvin tablets BP (dermofulvin forte) (2600x10x10 TAB)	$18.2K	1
Sildenafil citrate oral spray tiagra7370x30 ML	$14.4K	1
Paracetamol tablets BP 500 MG (dolomol	$13.6K	1
Betamethasone,dipropionate,gentamycin	$12.5K	2
Dextromethorphan hydrobromide extended	$11.6K	2
Anticold tablets (tussidryl-pe cold	$10.4K	2
Guaifenesin with bromhexine hydrochloride syruptussidryl12235x200 ML	$10.1K	1
Omeprazole capsules (omlink-20)	$9.8K	1

Makans Limited imports 148 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bromhexine	Respiratory & OTC	$500.0K	10	3.1%	4
2	Guaifenesin	Respiratory & OTC	$350.0K	7	1.3%	9

Makans Limited imports 2 pharmaceutical products across 1 categories into Fiji totaling $850.0K.

Makans Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Makans Limited, also known as Makans Drugs & Pharmaceutical Supplies, is a prominent pharmaceutical importer and distributor based in Lautoka, Fiji. Established in the late 1970s, the company has been dedicated to providing high-quality medicines to meet the health needs of the Fijian population. Over the years, Makans has expanded its operations to include a diverse range of pharmaceuticals, medical consumables, and consumer healthcare products, as well as exporting to other South Pacific islands.

The company operates through two main divisions: the Healthcare Division, which focuses on the development, marketing, and supply of medicines and medical consumables, and the Consumer Division, which deals with fast-moving consumer goods and beauty/personal care products. Makans is committed to continuous product innovation to meet the health needs of the community and satisfy consumer well-being.

2Distribution Network

Makans Limited's distribution network is strategically located to serve the Fijian market effectively. The company's primary warehouse is situated at 103 Vitogo Parade, Lautoka, Fiji, serving as the central hub for its operations. Additionally, Makans operates a branch at 24 Jai Hanuman Road, Suva, Fiji, expanding its reach to the capital city. These locations enable Makans to manage logistics efficiently and ensure timely delivery of products across Fiji.

3Industry Role

Makans Limited plays a pivotal role in Fiji's pharmaceutical supply chain as a primary wholesaler and distributor. By importing a wide array of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections, Makans ensures the availability of essential medicines throughout the country. The company's operations are integral to maintaining the supply of quality healthcare products to both public and private healthcare sectors in Fiji.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Makans Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Makans Limited's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from India. The company's total import value from India stands at $850,000 USD, encompassing 17 shipments and 148 unique formulations. This concentration indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities and cost-effectiveness.

The shipment data reveals a stable relationship with its primary supplier, Lincoln Pharmaceuticals Limited, which accounts for 99.9% of the total import value. This consistent sourcing pattern suggests a strong and reliable partnership, reducing the risks associated with supplier variability. However, the limited diversification in sourcing could pose challenges if there are disruptions in the Indian pharmaceutical market or with the primary supplier.

2Supply Chain Resilience

Makans Limited's supply chain resilience is closely tied to its reliance on Indian suppliers, particularly Lincoln Pharmaceuticals Limited. The company's import data indicates a heavy dependence on this single supplier, which could be a strategic choice to ensure consistency and quality. However, this concentration also exposes Makans to potential risks, such as supply chain disruptions due to geopolitical issues, regulatory changes, or natural disasters affecting India.

Importing Pharmaceuticals into Fiji — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Fiji

1Regulatory Authority & Framework

The Fiji Medicines Regulatory Authority (Fiji MRA), operating under the Ministry of Health and Medical Services, is responsible for regulating medicinal products in Fiji. The Fiji MRA's mandate includes drug registration, issuance of import permits, inspections of manufacturing and distribution premises, and ensuring that medicinal products meet prescribed standards of quality, safety, and efficacy. (health.gov.fj)

The regulatory framework governing pharmaceutical imports in Fiji is primarily outlined in the Medicinal Products Act 2011. This legislation requires that all medicinal products imported into Fiji be registered with the Fiji MRA and meet specific standards before they can be distributed or sold.

2Import Licensing & GMP

Import licensing in Fiji is governed by the Medicinal Products Act 2011, which mandates that all medicinal products imported into the country must be registered with the Fiji MRA. This process ensures that imported products meet the required standards of quality, safety, and efficacy.

The Fiji MRA recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Suppliers seeking to export pharmaceutical products to Fiji must ensure that their manufacturing facilities hold valid GMP certifications from these recognized organizations.

Makans Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Makans Limited's product strategy focuses on the Respiratory & OTC therapeutic category, with a portfolio concentration of 100% in this area. The company's top imported products include Bromhexine and Guaifenesin, both of which are commonly used in the treatment of respiratory conditions. This focus aligns with the prevalent health needs in Fiji, where respiratory illnesses are a significant concern.

The demand for these products is driven by factors such as seasonal variations, environmental conditions, and the overall health profile of the Fijian population. By concentrating on this therapeutic area, Makans can effectively address a critical segment of the healthcare market and ensure the availability of essential medicines.

2Sourcing Profile

Makans Limited's sourcing strategy is centered on importing generic pharmaceutical formulations from India. The company's preference for finished pharmaceutical products, including tablets, capsules, syrups, and injections, allows for a streamlined supply chain and quicker market entry. India's well-established pharmaceutical industry, characterized by its adherence to international quality standards and cost-effectiveness, makes it an ideal sourcing partner for Makans.

This approach enables Makans to offer a diverse range of pharmaceutical products to the Fijian market, catering to various therapeutic needs and consumer preferences.

Market Positioning

Seller's Guide — How to Become a Supplier to Makans Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Makans Limited, especially if they can offer products that complement the existing portfolio or introduce innovative formulations. Gaps in Makans' current sourcing may include specific dosage forms, combination therapies, or products targeting other therapeutic areas.

By identifying these gaps and aligning their offerings with Makans' strategic focus, new suppliers can establish mutually beneficial partnerships and gain access to the Fijian and broader South Pacific markets.

2Requirements & Qualifications

Indian exporters seeking to supply Makans Limited and the Fijian market must ensure that their manufacturing facilities hold valid GMP certifications from recognized international bodies such as the WHO or PIC/S. Additionally, products must be registered with the Fiji MRA and comply with the Medicinal Products Act 2011. This includes obtaining import

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Makans Limited

What products does Makans Limited import from India?

Makans Limited imports 2 pharmaceutical products across 1 categories. Top imports: Bromhexine ($500.0K), Guaifenesin ($350.0K).

Who supplies pharmaceuticals to Makans Limited from India?

Makans Limited sources from 2 verified Indian suppliers. The primary supplier is Lincoln Pharmaceuticals Limited (99.9% of imports, $854.9K).

What is Makans Limited's total pharmaceutical import value?

Makans Limited's total pharmaceutical import value from India is $850.0K, based on 17 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Makans Limited focus on?

Makans Limited imports across 1 categories. The largest: Respiratory & OTC (100.0%).

Get Full Makans Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.